Recognizing and Grading CAR T-Cell Toxicities: An Advanced Practitioner Perspective

Over the past decade, chimeric antigen receptor (CAR) T-cell therapy has significantly improved the outlook for many patients with relapsed and/or refractory B-cell malignancies. The use of CAR T-cell therapy and other therapeutic immune effector cells will likely continue to expand with the develop...

Descripción completa

Detalles Bibliográficos
Autores principales: Sievers, Savannah, Watson, Grace, Johncy, Swapna, Adkins, Sherry
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2020
Materias:
Oncology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7327099/
https://www.ncbi.nlm.nih.gov/pubmed/32670871
http://dx.doi.org/10.3389/fonc.2020.00885

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7327099/
https://www.ncbi.nlm.nih.gov/pubmed/32670871
http://dx.doi.org/10.3389/fonc.2020.00885

Ejemplares similares